About me
Angel Lucio is the CEO of Tetraneuron, a Spanish biotech company, advancing gene therapy solutions for Alzheimer’s disease and other neurodegenerative diseases. After several years supporting the company as an advisor and board member, Angel now leads its next phase of growth, as the company prepares its lead candidate TET101 for first-in-human trials. Over the past 17+ years, Angel have held leadership roles across Europe and Asia at Johnson & Johnson Innovative Medicine, Takeda, Sanofi, and others, building expertise in business development, M&A, licensing, strategy, and commercial operations. He has led global initiatives across multiple therapeutic areas, successfully bridging science and business to drive innovation. As a seed investor in early-stage biotech and health tech companies, he is committed to supporting transformative ideas that address critical unmet needs.
